At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 195 enrolled
Drug / intervention
MK-8237 6 DU +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (Protocol 008)
In Brief
A Phase 1 clinical trial evaluating MK-8237 6 DU, MK-8237 12 DU, and 1 other intervention for Rhinitis, Allergic, Perennial and Rhinitis, Allergic, Nonseasonal. Completed, enrolled 195 participants.
Detailed Summary
The purpose of this study is to evaluate the safety of two doses (6 Development Units \[DU\] and 12 DU) of MK-8237 sublingual tablets compared to Placebo in adolescents with house dust mite-induced allergic rhinitis/rhinoconjunctivitis. The primary hypothesis is that at least one dose of MK-8237 sublingual tablet is safe and well-tolerated in adolescents with house dust mite-induced allergic rhinitis/rhinoconjunctivitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 2012
Enrollment StartOct 2012
Primary CompletionMay 2013
TodayJul 2026
First PostedSep 5, 2012
Enrollment StartOct 1, 2012
Primary CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 13.8 years ago
Interventions
MK-8237 6 DUbiological
MK-8237 12 DUbiological
Placebobiological